entertainment -WSS

entertainment

author：comprehensive 2025-09-30 01:13:08 - browse：92725

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Study: Pain burden is higher in Black NFL players than white ones

knowledge

WSS

Diversity in medical illustrations gets boost from Chidiebere Ibe

It's time to get medical device identifiers over the finish line

Elizabeth Holmes on track for early release from her 11

New research casts further doubt on a common procedure used with IVF

Winners, losers from Medicare’s list of drugs subject to price talks

What AAP's gender

entertainment

entertainment

explore

Hepatitis C has a cure — but many Americans still lack access to it

What to know about OceanGate, the company behind the missing Titanic submersible

Continuity nursing helped my family in our darkest PICU moments

Beach reads and more: STAT's 2023 summer book list

At least 13 dead in Texas as scorching temps continue

FDA panel gives mixed vote on blood pressure devices

Alkermes shareholders re

Apellis safety probe of eye disease drug centers on injection needle

Sports medicine is finally prioritizing gender equality

Oak trusses raised to roof of fire

focus

AstraZeneca challenges Medicare drug negotiation program

AstraZeneca bets AAV gene therapy will still deliver the goods

Study: Pain burden is higher in Black NFL players than white ones

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

HCA discloses massive data breach affecting 11 million patients

AstraZeneca bets AAV gene therapy will still deliver the goods

focus

knowledge

knowledge

entertainment